In our study, we observed that the anti-melanoma efficacy of ZD55-IL-24 in local tumors is far higher than that of anti-PD-1 antibody in B16-bearing immunocompetent mouse model (Figs. 1a–e and 3b), indicating ZD55-IL-24 has an obvious advantage in antitumor efficacy. This evidence concerns the gene IL24 and melanoma.